Relieving nasal congestion in children with seasonal and perennial allergic rhinitis: efficacy and safety studies of mometasone furoate nasal spray

Eli O Meltzer, Carlos E Baena-Cagnani, Davis Gates, Ariel Teper, Eli O Meltzer, Carlos E Baena-Cagnani, Davis Gates, Ariel Teper

Abstract

Background: In surveys of children with allergic rhinitis (AR), nasal congestion has been identified as the most frequently experienced and bothersome symptom. This analysis was conducted to investigate the effect of mometasone furoate nasal spray (MFNS) on congestion in children with AR.

Methods: Two multicenter, double-blind, placebo-controlled studies randomly assigned children to MFNS 100 μg or placebo, 1 spray/nostril QD for 4 weeks (Study 1: ages 6-11 years with seasonal AR [SAR] ≥1 year; Study 2: ages 3-11 years with perennial AR [PAR] ≥1 year). Least square (LS) means were obtained from an ANCOVA model with treatment and study center effects, with baseline score as a covariate. We conducted post hoc evaluation of changes from baseline in AM/PM PRIOR (average of reflective AM and PM scores) nasal congestion (0=none to 3=severe).

Results: Study 1: MFNS (n=134) reduced congestion significantly more than placebo (n=135) on day 2 (P=.004) and on 23/29 days (P≤.037). Change from baseline was -0.53 and -0.28 for MFNS and placebo (P<.001) over days 1-15 and -0.64 and -0.38 for MFNS and placebo (P<.001) over days 1-29. Study 2: MFNS (n=185) reduced congestion significantly more than placebo (n=189) on day 3 (P=.015) and on 22/29 days (P≤.047). Change from baseline was -0.56 and -0.36 for MFNS and placebo (P<.001) over days 1-15 and -0.64 and -0.45 for MFNS and placebo (P<.001) over days 1-29. MFNS was well tolerated, with no unusual or unexpected adverse events.

Conclusion: MFNS effectively relieved nasal congestion and was well tolerated in children with SAR or PAR.

Figures

Figure 1
Figure 1
Study designs. BDP, beclomethasone dipropionate; MFNS, mometasone furoate nasal spray; PAR, perennial allergic rhinitis; SAR, seasonal allergic rhinitis. Gray lines indicate study arms or phases not included in this analysis of congestion results.
Figure 2
Figure 2
Change from baseline congestion score over days 1–15 and 1–29. *P<.05 vs. placebo. MFNS, mometasone furoate nasal spray; PAR, perennial allergic rhinitis; SAR, seasonal allergic rhinitis.
Figure 3
Figure 3
Daily change from baseline in AM/PM congestion score, Study 1 (SAR). Treatment difference P<.05 on all days except days 1, 10, 15, 18, 22, and 23. MFNS, mometasone furoate nasal spray; SAR, seasonal allergic rhinitis.
Figure 4
Figure 4
Daily change from baseline in AM/PM congestion score, Study 2 (PAR). Treatment difference P<.05 on all days except days 1, 2, 7, 17, 18, 20, and 29. MFNS, mometasone furoate nasal spray; PAR, perennial allergic rhinitis.

References

    1. Meltzer EO, Blaiss MS, Derebery MJ, Mahr TA, Gordon BR, Sheth KK. et al.Burden of allergic rhinitis: results from the pediatric allergies in America survey. J Allergy Clin Immunol. 2009;6:S43–S70. doi: 10.1016/j.jaci.2009.05.013.
    1. Björkstén B, Clayton T, Ellwood P, Stewart A, Strachan D. ISAAC Phase III Study Group. Worldwide time trends for symptoms of rhinitis and conjunctivitis: phase III of the international study of asthma and allergies in childhood. Pediatr Allergy Immunol. 2008;6:110–124. doi: 10.1111/j.1399-3038.2007.00601.x.
    1. Mansfield LE, Diaz G, Posey CR, Flores-Neder J. Sleep disordered breathing and daytime quality of life in children with allergic rhinitis during treatment with intranasal budesonide. Ann Allergy Asthma Immunol. 2004;6:240–244. doi: 10.1016/S1081-1206(10)61554-2.
    1. Gupta N, Smith AW, Kapur P, Kearney S, Silverman B, Emre U, Schneider AT. Allergic rhinitis and inner-city children—is there a relationship to sleep-disordered breathing? Pediatr Asthma Allergy Immunol. 2009;6:7–14. doi: 10.1089/pai.2008.0506.
    1. de Freitas FCN, Bastos EP, Primo LS, de Freitas VL. Evaluation of the palate dimensions of patients with perennial allergic rhinitis. Int J Paediatr Dent. 2001;6:365–371. doi: 10.1046/j.0960-7439.2001.00292.x.
    1. Meltzer EO, Berger WE, Berkowitz RB, Bronsky EA, Dvorin DJ, Finn AF, Galant SP, Grossman J, Hampel FC, Ratner PH. et al.A dose-ranging study of mometasone furoate aqueous nasal spray in children with seasonal allergic rhinitis. J Allergy Clin Immunol. 1999;6:107–114. doi: 10.1016/S0091-6749(99)70121-1.
    1. Baena-Cagnani CE, Patel P. Efficacy and long-term safety of mometasone furoate nasal spray in children with perennial allergic rhinitis. Curr Med Res Opin. 2010;6:2047–2055. doi: 10.1185/03007995.2010.487661.
    1. Nasonex [prescribing information] Whitehouse Station, NJMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (formerly Schering Corporation); 2011.
    1. Meltzer EO, Shekar T, Teper AA. Mometasone furoate nasal spray for moderate-to-severe nasal congestion in subjects with seasonal allergic rhinitis. Allergy Asthma Proc. 2011;6:159–167. doi: 10.2500/aap.2011.32.3424.
    1. Wandalsen GF, Mendes AI, Solé D. Objective improvement in nasal congestion and nasal hyperreactivity with use of nasal steroids in persistent allergic rhinitis. Am J Rhinol Allergy. 2010;6:e32–e36. doi: 10.2500/ajra.2010.24.3427.
    1. Schenkel EJ, Skoner DP, Bronsky EA, Miller SD, Pearlman DS, Rooklin A, Rosen JP, Ruff ME, Vandewalker ML, Wanderer A. et al.Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics. 2000;6:E22. doi: 10.1542/peds.105.2.e22.
    1. Brannan MD, Herron JM, Affrime MB. Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children. Clin Ther. 1997;6:1330–1339. doi: 10.1016/S0149-2918(97)80008-2.
    1. Sibbald B, Rink E. Epidemiology of seasonal and perennial rhinitis: clinical presentation and medical history. Thorax. 1991;6:895–901. doi: 10.1136/thx.46.12.895.
    1. Scadding GK, Richards DH, Price MJ. Patient and physician perspectives on the impact and management of perennial and seasonal allergic rhinitis. Clin Otolaryngol Allied Sci. 2000;6:551–557. doi: 10.1046/j.1365-2273.2000.00417.x.
    1. Ciprandi G, Cirillo I, Vizzaccaro A, Tosca M, Passalacqua G, Pallestrini E, Canonica GW. Seasonal and perennial allergic rhinitis: is this classification adherent to real life? Allergy. 2005;6:882–887. doi: 10.1111/j.1398-9995.2005.00602.x.
    1. Bousquet J, Van Cauwenberge P, Khaltaev N. Aria Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;6:S147–S334. doi: 10.1067/mai.2001.118891.
    1. Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, van Wijk RG, Ohta K, Zuberbier T, Schünemann HJ. Global Allergy and Asthma European Network. Grading of recommendations assessment, development and evaluation working group. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;6:466–476. doi: 10.1016/j.jaci.2010.06.047.
    1. da Silva CH, Silva TE, Morales NM, Fernandes KP, Pinto RM. Quality of life in children and adolescents with allergic rhinitis. Braz J Otorhinolaryngol. 2009;6:642–649. doi: 10.1590/S1808-86942009000500005.
    1. Shedden A. Impact of nasal congestion on quality of life and work productivity in allergic rhinitis: findings from a large online survey. Treat Respir Med. 2005;6:439–446. doi: 10.2165/00151829-200504060-00007.
    1. Li AM, Au CT, So HK, Lau J, Ng PC, Wing YK. Prevalence and risk factors of habitual snoring in primary school children. Chest. 2010;6:519–527. doi: 10.1378/chest.09-1926.
    1. Abreu RR, Rocha RL, Lamounier JA, Guerra AF. Etiology, clinical manifestations and concurrent findings in mouth-breathing children. J Pediatr (Rio J) 2008;6:529–535. doi: 10.1590/S0021-75572008000700010.
    1. Juliano ML, Machado MA, de Carvalho LB, Zancanella E, Santos GM, do Prado LB, do Prado GF. Polysomnographic findings are associated with cephalometric measurements in mouth-breathing children. J Clin Sleep Med. 2009;6:554–561.
    1. Juliano ML, Machado MA, Carvalho LB, Prado LB, do Prado GF. Mouth breathing children have cephalometric patterns similar to those of adult patients with obstructive sleep apnea syndrome. Arq Neuropsiquiatr. 2009;6:860–865. doi: 10.1590/S0004-282X2009000500015.
    1. Fernández RP, Díez Jde M, Alvarez-Perea A, Tapia PM, García RJ, Gómez-Piñán VS. Risk factors for asthma onset between the ages of 12 and 40. Results of the FENASMA study. Arch Bronconeumol. 2011;6:433–440.
    1. Modrzynski M, Zawisza E. An analysis of the incidence of adenoid hypertrophy in allergic children. Int J Pediatr Otorhinolaryngol. 2007;6:713–719. doi: 10.1016/j.ijporl.2006.12.018.
    1. Tomonaga K, Kurono Y, Mogi G. The role of nasal allergy in otitis media with effusion. A clinical study. Acta Otolaryngol Suppl. 1988;6:41–47.
    1. Brawley A, Silverman B, Kearney S, Guanzon D, Owens M, Bennett H, Schneider A. Allergic rhinitis in children with attention-deficit/hyperactivity disorder. Ann Allergy Asthma Immunol. 2004;6:663–667. doi: 10.1016/S1081-1206(10)61434-2.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться